Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:STIM

Neuronetics Q2 2026 Earnings Report

Neuronetics logo
$1.97 +0.15 (+8.24%)
Closing price 04:00 PM Eastern
Extended Trading
$1.96 -0.01 (-0.51%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Neuronetics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.11
Beat/Miss
N/A
One Year Ago EPS
N/A

Neuronetics Revenue Results

Actual Revenue
N/A
Expected Revenue
$40.17 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neuronetics Announcement Details

Quarter
Q2 2026
Date
8/11/2026
Time
Before Market Opens
Conference Call Date
Tuesday, August 11, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

Neuronetics Earnings Headlines

Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call
July 28 at 9:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334245/0/en/Neuronetics-to-Report-Second-Quarter-2026-Financial-and-Operating-Results-and-Host-Conference-Call.html
Neuronetics Opens Greenbrook Mental Wellness Centers National Center of Excellence in Rockville, Maryland
July 28 at 8:50 AM  |  quiverquant.comQ
The Pentagon is desperate
The Pentagon has admitted the US trails Russia and China in hypersonic weapons, and its research budget has nearly tripled in five years. One small Florida company, trading under $5, is already under contract with Lockheed Martin, GE Aerospace, and the US Air Force to help test this technology at extreme altitudes. The company also launches commercial satellites and is nearing a major licensing milestone that could reshape its valuation.tc pixel
July 30 at 1:00 AM  |  Freedom Financial (Ad)
Neuronetics Announces Date for Second Quarter 2026 Financial and Operating Results Conference Call
July 28 at 8:50 AM  |  quiverquant.comQ
Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland
July 28 at 8:32 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334270/0/en/greenbrook-opens-national-center-of-excellence-for-advanced-interventional-psychiatry-in-rockville-maryland.html
BTIG Research Begins Coverage on Neuronetics (NASDAQ:STIM)
July 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30913280
See More Neuronetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neuronetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuronetics and other key companies, straight to your email.

About Neuronetics

Neuronetics (NASDAQ:STIM) is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation. The company’s platform is designed for use in outpatient clinics, hospitals and psychiatry practices across the United States. Neuronetics maintains a specialized field sales force and collaborates with key channel partners to support physician training, patient education and therapy delivery. In addition to its commercial activities, the company continues to explore new indications and protocol optimizations to expand its therapeutic offerings.

Guided by a leadership team with deep experience in medical devices and neuroscience, Neuronetics strives to improve patient outcomes through research, regulatory engagement and post-market data collection. The company’s ongoing efforts include refining device features, enhancing treatment compliance and evaluating the use of its technology in other neuropsychiatric conditions. Neuronetics is publicly traded on the Nasdaq under the symbol STIM.

View Neuronetics Profile
Earnings Tools